Natera Submits Application To Japan’s Pharmaceuticals And Medical Devices Agency For Approval Of The Signatera Test In Muscle-Invasive Bladder Cancer As A Companion Diagnostic
The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country’s first PMDA-approved molecular residual disease (MRD) test.The MIBC
Natera is asking Japan's health officials to approve its Signatera test to help doctors find cancer that might come back in bladder-cancer patients. This shows the company is expanding its test into new countries and cancer types, which could help more patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.